Almost all liver cancers develop after decades of chronic liver disease, but a new discovery by Columbia researchers may lead to treatments that could break the link.
Oct 21, 2022
0
478
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In Germany, there are currently around 9,000 new HCC diagnoses per year, and almost 8,000 people affected do not survive the disease. Before the ...
Oct 19, 2022
0
57
Alcohol consumption and hepatitis C viral infection are known risk factors for causing hepatocellular carcinoma, the most common form of liver cancer. Apart from these, obesity-associated nonalcoholic fatty liver disease ...
Oct 17, 2022
0
49
A hormone secreted by fat cells can restrain the growth of liver tumors in mice, according to a new study from the University of Michigan Life Sciences Institute.
Aug 15, 2022
0
71
Treating liver cancer tumors to shrink them in order to allow the patient to qualify for a liver transplant leads to excellent 10-year post-transplant outcomes, according to new Mount Sinai research published in JAMA Surgery. ...
Jul 22, 2022
0
69
Experts from Cedars-Sinai Cancer have analyzed patient samples, along with studies conducted in animal models, to identify a novel immune checkpoint pathway to treat hepatocellular carcinoma, the most common form of liver ...
Jun 20, 2022
0
108
A team of researchers from the College of Design and Engineering, the N.1 Institute for Health and the Cancer Science Institute of Singapore at the National University of Singapore has recently engineered in vitro tumor models ...
Jun 2, 2022
0
33
Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.
Apr 13, 2022
0
62
A combination of the kinase-inhibitor drug cabozantinib and the immunotherapy drug nivolumab can make curative surgery possible in some liver cancer patients who would normally not be considered surgery candidates.
Jul 29, 2021
0
249
Immunotherapy is not only significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), but actually appears to fuel tumor growth, according to a Mount ...
Mar 24, 2021
0
63
